| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $28,575,521 ) (Continued on the next page) |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K22CA276360 | Unraveling the functional contribution of extracellular vesicles in pancreatic cancer | 000 | 2 | NIH | 12/9/2025 | $173,016 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA283514 | Examining the Role of Nono Pathway on the Innate Immunity Against Oncolytic Adenoviruses | 000 | 2 | NIH | 12/11/2025 | $171,982 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA307060 | Mechanistic basis and therapeutic strategies for PPP2R1A mutation in gynecological cancer | 000 | 1 | NIH | 3/16/2026 | $653,967 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01DE032168 | Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-Enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI) | 000 | 4 | NIH | 2/6/2026 | $634,331 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA295874 | Proteotoxic Metabolites in Genome Instability and Disease | 000 | 2 | NIH | 12/9/2025 | $519,032 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K99CA296780 | The role of oral microbiota in metastatic brain tumors | 000 | 2 | NIH | 2/6/2026 | $100,823 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA299972 | Deregulation of Sulfatide Synthesis in the Development and Progression of Pancreatic Cancer Precursor Lesions | 000 | 2 | NIH | 1/28/2026 | $609,807 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA258540 | Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma | 000 | 5 | NIH | 1/28/2026 | $518,944 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA262437 | ROLE OF SORD IN SUGAR-MEDIATED CANCER METASTASIS | 000 | 6 | NIH | 1/28/2026 | $367,804 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269646 | Targeting ferroptosis in cancer therapy | 000 | 4 | NIH | 1/23/2026 | $444,596 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA301555 | Delivery optimization of a transarterial ablative therapy | 000 | 2 | NIH | 1/26/2026 | $474,524 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | F31DE035777 | The Development of an early detection tool for oral-dental radiation induced injury | 001 | 1 | NIH | 1/21/2026 | $0 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DE034780 | Harvard MD Anderson Collaborative to Reduce LyMphatic MOrbidity in Head and Neck Cancer with Artificial Intelligence (HARMONiC-AI) | 000 | 2 | NIH | 1/27/2026 | $644,975 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01HD110520 | Molecular Mechanism of long Noncoding RNAs in Phenylketonuria | 000 | 4 | NIH | 1/28/2026 | $419,339 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA288617 | TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer | 000 | 3 | NIH | 3/4/2026 | $370,575 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA295906 | Targeting SMARCA2 to overcome resistance of SMARCA4-mutant lung cancer to KRAS G12C inhibitors | 000 | 2 | NIH | 12/19/2025 | $137,585 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01HL163857 | Premature aging disorders, metabolites, and atherosclerosis | 000 | 4 | NIH | 2/16/2026 | $670,228 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA255960 | Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients | 000 | 5 | NIH | 12/11/2025 | $428,160 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21LM014699 | Novel designs for multi-arm multi-dose multi-stage platform trials | 000 | 2 | NIH | 1/13/2026 | $220,725 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K99CA286745 | Mechanisms of CDH1-inactivated advanced gastric adenocarcinoma tumorigenesis | 000 | 2 | NIH | 1/12/2026 | $116,697 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA255322 | Gut Microbiome and Cancer Immunotherapy Outcomes in Advanced Renal Cell Carcinoma | 000 | 5 | NIH | 3/3/2026 | $927,329 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA295834 | Endogenous Circular RNAs limit abemaciclib anti tumor immune responses | 000 | 2 | NIH | 2/26/2026 | $567,059 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DE030875 | Functional roles of GOF TP53 mutations in metastasis and immunosuppression of head and neck cancers | 000 | 5 | NIH | 2/24/2026 | $556,146 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01EB034665 | Single-use Microfluidic Device for Radiopharmaceutical Production | 000 | 2 | NIH | 2/20/2026 | $618,871 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS122052 | Analyzing Adhesion and Signaling Functions for PTPN12 in Invasive Glioma Cells | 001 | 5 | NIH | 2/28/2026 | $40,094 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA195524 | Early Detection of Hepatocellular Carcinoma | 000 | 10 | NIH | 2/26/2026 | $663,280 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DE034408 | Elucidating subclonal evolution and fitness dynamics in oral carcinogenesis | 000 | 1 | NIH | 2/18/2026 | $735,436 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278971 | Esophageal Squamous Cell Cancer Initiation and Immune Landscape Remodeling | 000 | 3 | NIH | 12/8/2025 | $468,540 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA271223 | Dissemination and implementation of DIGEST™ as an evidence-based measurement tool for dysphagia in cancer | 000 | 4 | NIH | 2/18/2026 | $569,551 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA288827 | Deciphering the Critical Determinants of Enteric and Tumor Niche Colonization by Microbes in Colorectal Cancer | 000 | 2 | NIH | 2/12/2026 | $613,739 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01CA275886 | Identifying and targeting collateral lethal vulnerabilities in cancers | 000 | 4 | NIH | 3/9/2026 | $967,037 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA269622 | An image-guided immunotherapy and hyperthermia delivery device to overcome barriers to tumor immunity for advanced hepatocellular carcinoma | 000 | 4 | NIH | 2/27/2026 | $395,807 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K01DK141967 | Multi-omic approaches to exploring the gut microbiome and metabolic dysfunction-associated steatotic liver disease (MASLD) | 000 | 1 | NIH | 3/10/2026 | $151,136 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R35GM156417 | Computational and experimental approaches for decoding the function and regulation of unconventional RNA translation | 000 | 2 | NIH | 1/15/2026 | $404,663 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | F99AG088439 | Elucidating Novel Regulators of Microglial Phagocytosis in Alzheimer’s Disease | 000 | 2 | NIH | 1/14/2026 | $37,746 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA264987 | Radiomic and genomic predictors of breast cancer risk | 000 | 6 | NIH | 1/15/2026 | $627,887 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA270010 | Exploring novel strategies for immunoprevention of estrogen receptor negative breast cancer | 000 | 4 | NIH | 1/20/2026 | $426,474 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278938 | Comparative Effectiveness of Sequential Pharmacotherapeutic Strategies and Virtually Delivered Treatment to Optimize Smoking Cessation | 001 | 3 | NIH | 1/19/2026 | $819,991 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R00CA287069 | A Chemoproteomic Approach to Identify Molecular Glues for Targeted Cancer Therapy | 000 | 3 | NIH | 1/7/2026 | $224,099 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA202919 | Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer | 001 | 11 | NIH | 1/8/2026 | $336,677 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA279749 | Integrating patient-reported outcomes and T-cell receptor sequencing to predict immune-related adverse events | 000 | 3 | NIH | 1/7/2026 | $572,176 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS122052 | Analyzing Adhesion and Signaling Functions for PTPN12 in Invasive Glioma Cells | 000 | 5 | NIH | 12/23/2025 | $360,856 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DE034408 | Elucidating subclonal evolution and fitness dynamics in oral carcinogenesis | 001 | 1 | NIH | 2/23/2026 | $0 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AI190103 | Machine learning for identifying antigen-antibody interactions from massive sequencing data | 003 | 3 | NIH | 2/24/2026 | $635,012 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269565 | The Role of HIF2 in Pancreatic Ductal Adenocarcinoma | 000 | 4 | NIH | 12/15/2025 | $515,400 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA299696 | Decoding the co-evolution of cancer subclones and their ecosystem in TNBC multi-organ metastasis | 000 | 2 | NIH | 3/3/2026 | $676,584 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA276235 | Cis-aconitate decarboxylase (ACOD1) in PMN-MDSC and prostate cancer progression | 000 | 4 | NIH | 12/15/2025 | $333,518 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA285980 | Use of Noninvasive Biomarkers and Advanced MRI for early detection of NF1-associated MPNSTs | 000 | 3 | NIH | 3/3/2026 | $580,422 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS122143 | Analyzing the Endothelial Cell-Expressed Prion Gene Prnd in Vascular Development | 000 | 5 | NIH | 12/19/2025 | $360,856 |
|
